Abstract
Hyperhidrosis is a psychological skin condition characterized by uncontrollable, excessive amounts of sweat in specific body locations. Although not a physically debilitating condition, those individuals affected with this condition commonly experience psychosocial stress during regular social encounters and exhibit low self-confidence, thus drastically decreasing the quality of life of these individuals (Coutinho dos Santos et al. Pediatr Dermatol 26(4):439–444, 2009; Glogau, Dermatol Surg 24(8):817–819, 1998; Kouris et al. Pediatr Dermatol 32(2):226–230, 2015). Hyperhidrosis is often diagnosed in patients suffering from psychosocial disorders such as social anxiety, suggesting a psychological factor may influence it’s onset. Various management options exist for the treatment of hyperhidrosis including fractionated microneedle radio (FMR) treatment, botulinum toxin type A (BTXA), surgery, oral administration of the anticholinergic drug glycopyrronium bromide (glycopyrrolate), aluminum chloride antiperspirants, iontophoresis, and endoscopic thoracic sympathectomy (Glogau, Dermatol Surg 24(8):817–819, 1998; Kouris et al. Pediatr Dermatol 32(2):226–230, 2015; Bajaj and Langtry, Br J Dermatol 157(1):118–121, 2007; Fatemi Naeini et al. Australas J Dermatol 56(4):279–284, 2015; Kobayashi et al. J Dermatol 21(8):575–581, 1994; Rompel and Scholz, J Eur Acad Dermatol Venereol 15(3):207–211, 2001). Currently, endoscopic thoracic sympathectomy is the only current, permanent treatment option. However, new therapeutic options on the horizon such as lasers and microwave thermolysis demonstrate promising results.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACTH:
-
Adrenocorticotropic hormone
- BTXA:
-
Botulinum toxin type A
- CRH:
-
Corticotrophin-releasing hormone
- DLQI:
-
Dermatology Life Quality Index
- HADS:
-
Hospital Anxiety and Depression Scale
- HDSS:
-
Hyperhidrosis Disease Severity Scale
- HPA:
-
Hypothalamic-pituitary-adrenal
- MMPI-2:
-
Minnesota Multiphasic Personality Inventory-2
- OCD:
-
Obsessive-compulsive disorder
- ORS:
-
Olfactory reference syndrome
- PAH:
-
Primary axillary hyperhidrosis
- SES:
-
Subjective evaluation scale
- VAS:
-
Visual Analogue Scale
Citations
Coutinho dos Santos LH, Gomes AM, Giraldi S, Abagge KT, Marinoni LP. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Pediatr Dermatol. 2009;26(4):439–44.
Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. Dermatol Surg. 1998;24(8):817–9.
Kouris A, Armyra K, Stefanaki C, Christodoulou C, Karimali P, Kontochristopoulos G. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series. Pediatr Dermatol. 2015;32(2):226–30.
Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol. 2007;157(1):118–21.
Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–84.
Kobayashi K, Omote K, Homma E, Abe T, Iitoyo M. Sympathetic ganglion blockade for the management of hyperhidrosis. J Dermatol. 1994;21(8):575–81.
Rompel R, Scholz S. Subcutaneous curettage vs. injection of botulinum toxin A for treatment of axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2001;15(3):207–11.
Nordqvist C. What is hyperhidrosis? What caues hyperhidrosis? 2014. Available from: http://www.medicalnewstoday.com/articles/182130.php.
Tronstad C, Helsing P, Tonseth KA, Grimnes S, Krogstad AL. Tumescent suction curettage vs. curettage only for treatment of axillary hyperhidrosis evaluated by subjective and new objective methods. Acta Derm Venereol. 2014;94(2):215–20.
Vary Jr JC. Selected disorders of skin appendages--acne, alopecia, hyperhidrosis. Med Clin North Am. 2015;99(6):1195–211.
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.
Singh S, Davis H, Wilson P. Axillary hyperhidrosis: a review of the extent of the problem and treatment modalities. Surgeon. 2015;13(5):279–85.
Munro DD, Verbov JL, O’Gorman DJ, du Vivier A. Axillary hyperhidrosis. Its quantification and surgical treatment. Br J Dermatol. 1974;90(3):325–9.
Britannica E. Sweat gland Britannica.com: Encyclopaedia Britannica; [Updated 8/19/2014; cited 2016 1/26/16]. Available from: http://www.britannica.com/science/sweat-gland.
Staff MC. Sweating and body odor Mayoclinic.org2014 [Cited 2016 1/26/16]. Available from: http://www.mayoclinic.org/diseases-conditions/sweating-and-body-odor/basics/causes/con-20014438.
Ruchinskas RA, Narayan RK, Meagher RJ, Furukawa S. The relationship of psychopathology and hyperhidrosis. Br J Dermatol. 2002;147(4):733–5.
Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9(3):e92412.
Bohaty BR, Hebert AA. Special considerations for children with hyperhidrosis. Dermatol Clin. 2014;32(4):477–84.
Lessa Lda R, Luz FB, De Rezende RM, Duraes SM, Harrison BJ, De Menezes GB, et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract. 2014;20(4):316–23.
Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany B. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol. 2005;152(2):342–5.
Ferrao YA, Shavitt RG, Prado H, Fontenelle LF, Malavazzi DM, de Mathis MA, et al. Sensory phenomena associated with repetitive behaviors in obsessive-compulsive disorder: an exploratory study of 1001 patients. Psychiatry Res. 2012;197(3):253–8.
Braganca GM, Lima SO, Pinto Neto AF, Marques LM, Melo EV, Reis FP. Evaluation of anxiety and depression prevalence in patients with primary severe hyperhidrosis. An Bras Dermatol. 2014;89(2):230–5.
Krogstad AL, Mork C, Piechnik SK. Daily pattern of sweating and response to stress and exercise in patients with palmar hyperhidrosis. Br J Dermatol. 2006;154(6):1118–22.
Reisfeld R, Berliner KI. Evidence-based review of the nonsurgical management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):157–66.
Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin. 2014;32(4):485–90.
Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ. 2005;172(1):69–75.
Hoorens I, Ongenae K. Primary focal hyperhidrosis: current treatment options and a step-by-step approach. J Eur Acad Dermatol Venereol. 2012;26(1):1–8.
Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new therapeutic options for primary hyperhidrosis. Curr Opin Pediatr. 2014;26(4):460–5.
Scuderi S, Manoharan P, Lim D, Manoharan S. A survey of patient satisfaction with use of microwave device for axillary hyperhidrosis. Australas J Dermatol. 2016.
Pariser DM, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):491–4.
Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):505–15.
Benohanian A. Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis. Br J Dermatol. 2007;156(3):593–6.
Smith KC, Comite SL, Storwick GS. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S88–91.
de Almeida AR, Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatol Clin. 2014;32(4):495–504.
Karpinski RHS. Surgical treatment of axillary hyperhidrosis treatment & management Medscape2014 [Cited 2016 1/23/16]. Available from: http://emedicine.medscape.com/article/1296530-treatment – d13.
Shi Z, Yan X, Ye X. Modified tumescent superficial suction with curettage treatment for axillary bromidrosis: clinical experience of 280 cases. Aesthetic Plast Surg. 2014;38(1):151–5.
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.
Johnson JE, O’Shaughnessy KF, Kim S. Microwave thermolysis of sweat glands. Lasers Surg Med. 2012;44(1):20–5.
Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatol Clin. 2014;32(4):533–40.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hsu, V.M., Shah, V.V., Aldahan, A.S., Mlacker, S., Samarkandy, S., Nouri, K. (2017). Hyperhidrosis and Stress. In: França, K., Jafferany, M. (eds) Stress and Skin Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-46352-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-46352-0_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46351-3
Online ISBN: 978-3-319-46352-0
eBook Packages: MedicineMedicine (R0)